Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer, Health Discovery, GeneGo, Chang Gung University, EBI, Entelos, Unilever, Hoffmann-LaRoche, Simulations Plus

Pfizer Licenses Health Discovery’s IP for R&D Use
Health Discovery said this week that Pfizer has licensed its pattern-recognition technology for use in its worldwide research and development activities.
The license includes HDC's support vector machine technology, its Fractal Genomic Modeling system, and “related methods for data analysis,” the company said.
Financial terms of the agreement were not disclosed.

Taiwan’s Chang Gung University Upgrades MetaCore License
GeneGo said this week that Chang Gung University in Taiwan has upgraded its MetaCore web portal license to a permanent in-house server installation.
The university has also licensed GeneGo’s MapEditor package for drawing and editing pathway maps.
GeneGo's Taiwanese distributor Tri-I Biotech helped negotiate the expanded license agreement.
The Chang Gung Bioinformatics Center is using GeneGo’s software in several research projects, including the identification of biomarkers for nasopharyngeal carcinoma, the Trichomonas vaginalis Systems Biology Project, and the Acanthamoeba Expressed Sequence Tag Project.

EBI, India’s National Center for Biological Sciences, to Exchange BioModels Data
The European Bioinformatics Institute said this week that its BioModels Database has entered a formal data-exchange agreement with the Database of Quantitative Chemical Signaling hosted by India’s National Center for Biological Sciences.
EBI said that the two databases will now simultaneously release computer models of biological processes and noted that the agreement “is the culmination of more than a year’s work to make the models in DOQCS available in Systems Biology Markup Language.
The merged collections of BioModels and DOQCS, will include more than 250 biological models, covering more than 5,000 reactions, EBI said.

Entelos Completes Skin Sensitization PhysioLab for Unilever
Entelos said this week that it has completed the development of its Skin Sensitization PhysioLab platform, which it has been developing with Unilever.
The model structures data “in a way that enables identification of the key factors associated with the development of skin sensitization and could potentially guide the future development of new models to aid in the safety assessment of consumer products,” Entelos said in a statement.
The Skin Sensitization PhysioLab platform models the physiology of skin allergy in order to identify chemical properties that are most likely to lead to a significant allergic response. It was developed by collating data from hundreds of peer-reviewed papers and includes a chemical exposure submodel, physical properties of the epidermis and the draining lymph node, and the cellular mechanisms giving rise to skin sensitization.
Entelos has delivered the platform to Unilever on a non-exclusive basis. It retains full rights to use the technology independently, including rights for all pharmaceutical applications.

Hoffmann-LaRoche Renews License for Simulations Plus’s GastroPlus Software
Simulations Plus said this week that F. Hoffmann-LaRoche has renewed and expanded its global licenses for the company’s GastroPlus software for another two years.
Financial terms of the agreement were not provided.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.